Phase 1 Trial of Oral EDG-5506 for Becker MD Enrolling at Texas Site
Edgewise Therapeutics announced the opening of a Phase 1 clinical trial to assess the safety and tolerability of EDG-5506, its investigational oral treatment for Becker muscular dystrophy (BMD). The study (NCT04585464) is now enrolling up to 152 healthy volunteers and adults with BMD, ages 19 to 55, at…